Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic
  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Says Recent Acquisition to Help Capitalize on ‘Tremendous’ Potential in iGaming Market

180 Life Sciences (NASDAQ: ATNF) today announced that it can now fully focus on developing its new iGaming business after officially regaining compliance with Nasdaq Listing Rule 5550(b)(1) on minimum stockholders’ equity. The company announced earlier this month that it will be strategically shifting towards the growing global iGaming sector as it seeks to leverage significant opportunities and establish itself as a key player in this market. 180 recently acquired a gaming platform that integrates the latest blockchain technology, thus promising transparency, security, and trust. The platform, expected to launch during Q1 2025, will accept cryptocurrency and fiat currency. The company will also continue to advance its legacy biotechnology business.

“We are thrilled to confirm that our recent acquisition of a leading iGaming platform technology is expected to allow us to rapidly pivot into this high-growth sector,” said Blair Jordan, Interim CEO of 180 Life. “We believe that this move places 180 at the forefront of technological innovation in the iGaming space, enabling us to be in a position to offer state-of-the-art gaming solutions in the near future and capitalize on what we believe is the tremendous market potential ahead.” 

To view the full press release, visit https://ibn.fm/jQJnM

About 180 Life Sciences Corp.

180 Life Sciences Corp. is a publicly traded company that focuses on developing new technologies across multiple sectors. With its current portfolio of inflammation-focused intellectual property and its recent acquisition of the Gaming Technology Platform, the company believes it is positioned for growth in both the biotech and iGaming industries. For more information, visit the company’s website at www.180LifeSciences.com

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.